is semaglutide under patent Off-patent in 2026: the next revolution in anti-obesity medications Semaglutide: Just Another Off-Patent Generic?

For example, in the SELECT trial (17,600 patients with cardiovascular disease and obesity but without T2D), weekly subcutaneous Semaglutide (2.4 mg) reduced the risk of major adverse cardiovascular events (MACE heart attack, stroke, or cardiovascular death) by 20% compared to placebo (HR 0.80

Bedaquiline, an FDA-approved antibiotic, inhibits mitochondrial function and potently blocks the proliferative expansion of stem-like cancer cells (CSCs) Aging (Albany NY) 2016;8:1593607

10.1038/cdd.2015.158 58 YangW

We've said that all along

56 This may be the secret of the extraordinary efficacy of tirzepatide, but it is still possible that the best ratio of GLP-1 and GIP activity in a dual agonist has not been discovered

11), recent X-ray crystallography and cryo-EM data revealed that GSH binds the ATD of GLR3.4 30 , another GLR protein with high sequence similarity to GLR3.3, reinforcing that GSH might bind the ATD domain of GLR3.3 for activation of ion channel